Retatrutide price and NHS access: nobody can quote you a real number
There is no announced brand, no announced price, and no supply chain. Anyone quoting a UK retatrutide price today is inventing it. Here is what we can honestly say about what it will eventually cost and who will get it.
Independently written · Last reviewed: · editorial policy
Key facts in 30 seconds
- No brand name and no price have been announced in any country — every number on a sales page or “price predictor” is invented.
- Precedent suggests a premium private launch at or above Mounjaro’s top-dose pricing, with pharmacy competition pulling prices down over 1–2 years.
- The NHS route is the slowest: MHRA authorisation, NICE appraisal, then phased commissioning — 2029 at the earliest.
- “Pre-order”, “reserve stock” and “founder pricing” offers are scams built on the fact that no real price exists.
- Authorised options today: Wegovy ≈£100–£170 and Mounjaro ≈£94–£230 per month, delivered, through verified pharmacies.
The only true statement about retatrutide pricing
As of September 2026, Eli Lilly has announced neither a brand name nor a price for retatrutide, in any market. There is no wholesale price, no pharmacy price, no NHS tariff entry, no patient-access-scheme document. Every number you have seen on a sales page, forum or “price predictor” article is speculation — and in the case of sellers, a hook.
What precedent suggests for the UK private market
When — and if — retatrutide is authorised, its UK pricing will most likely follow the tirzepatide template: launched first as a premium private medicine through GPhC-registered online pharmacies, with discounting and competition pulling prices down over the first one to two years. For reference, the established UK private market in September 2026 looks roughly like this:
| Medicine | Typical private range (delivered, per month) | Notes |
|---|---|---|
| Wegovy (semaglutide) | ≈£100–£170 | varies by dose; lower doses sit at the bottom of the range |
| Mounjaro (tirzepatide) | ≈£94–£230 | price rises with dose; independently tracked at monj.co.uk |
| Retatrutide | — | no price exists; expect a premium launch price if authorised |
Expect retatrutide, if approved, to launch at or above Mounjaro's top-dose pricing: it will be the newest, strongest medicine in the class, and manufacturers price accordingly. Equally, expect pharmacy competition to bite within a year or two, as it has for every other GLP-1 medicine in the UK. All of that is pattern-reading, not information.
Why NHS access will be the slowest route
NHS access requires three separate gates: MHRA authorisation, a positive NICE technology appraisal, and then NHS England commissioning with a phased rollout. Tirzepatide shows how long each step takes in practice: authorised by the MHRA and recommended by NICE in late 2024, yet still being rolled out to NHS patients in tightly prioritised phases — highest BMI and greatest clinical need first — with full availability years away. Retatrutide would follow the same path, starting no earlier than 2029 on current timelines, and its premium price will make NICE's cost-effectiveness calculation harder, not easier.
The scam economy that pricing uncertainty creates
“Reserve your retatrutide now”, “pre-order UK stock”, “founder pricing before launch” — every variation is a lie built on one true fact: nobody knows the price, so any number sounds plausible. Pre-orders for an unapproved medicine are simply a way to take money for an illegal or nonexistent product. The full breakdown, including how to report sellers, is on our fake-products warning page.
What to do with the money and motivation you have right now
- If you want treatment now: Mounjaro and Wegovy are authorised and available privately. Compare verified pharmacy prices at monj.co.uk.
- If you specifically want retatrutide: set a reminder for 2028, and in the meantime ignore every seller. Nothing they ship is retatrutide.
- If cost is the barrier: talk to your GP about NHS eligibility for existing options, and about the non-medicine support the NHS does provide.
Cite this page
Johnson N. Yezz — independent UK retatrutide information. Medstack Ltd, 10 September 2026. https://yezz.co.uk/price-and-nhs-access
Sources
Every factual claim on this page traces to one of these primary sources. We link out so you can check the original.
- 1.Retatrutide UK: availability and legal status — “any website quoting a UK retatrutide price today is quoting a number that does not exist” — updated 31 July 2026
- 2.monj.co.uk — live UK Mounjaro prices — GPhC-verified pharmacy price ranges used above
- 3.Retatrutide regulatory timeline — filing plan and NICE/NHS sequencing
- 4.NICE — how medicines get NHS access in England and Wales